NexEos Diagnostics has filed a notice of an exempt offering of securities to raise $4,916,907.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, NexEos Diagnostics is raising up to $4,916,907.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stephen Tullman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About NexEos Diagnostics
NexEos Bio is a privately held medical diagnostics and therapeutics company dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Our Mission is to transform the worlds foremost understanding of eosinophils in human biology into compassionate care solutions for patients through innovative diagnostic and treatment pathways.
To learn more about NexEos Diagnostics, visit http://www.nexeosbio.com/
Company Linkedin Page: https://www.linkedin.com/company/nexeos-bio/
Contact:
Stephen Tullman, Chief Executive Officer
610-457-9891
https://www.linkedin.com/in/steve-tullman-4668a518/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.